- Home
- Products
ZEJULA (Niraparib)
ZEJULA (Niraparib)
- Medicine Name: ZEJULA
- Generic Name: Niraparib
- Dosage Form & Strength: 100 mg Capsules
- Form: Oral
- Manufactured By: Tesaro, Inc.
- FDA Approval: Yes (Approved in 2017)
ZEJULA (Niraparib) is a PARP inhibitor used in the treatment of certain gynecologic cancers.
It is indicated:
- As maintenance therapy for adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in complete or partial response to first-line platinum-based chemotherapy
- As maintenance therapy in adults with recurrent ovarian cancer who are responding to platinum-based chemotherapy
- As treatment in adults with advanced ovarian, fallopian tube, or peritoneal cancer associated with homologous recombination deficiency (HRD) positivity, including BRCA mutations, and who have been treated with three or more prior chemotherapy regimens
Initiation of Niraparib should only begin once the patient has fully recovered from hematologic toxicity caused by previous chemotherapy
CBC (Complete Blood Count) should be monitored weekly during the first month, then monthly for the next 11 months, and periodically thereafter
Blood pressure and heart rate monitoring is recommended weekly for two months, monthly for one year, and periodically afterward
Monitor patients for cardiovascular risks, including hypertension, arrhythmias, and coronary insufficiency
Niraparib may cause fetal harm and should not be used during pregnancy
Breastfeeding should be avoided during treatment and for at least one month after the last dose
Required documents for import to India:
- Valid medical prescription from a registered doctor
- Diagnostic reports confirming indication for therapy
- Government-issued ID of the patient
Order Confirmation:
- Processed only after receipt of valid documents and import permit (if applicable)
Availability:
ZEJULA is available in India through named patient supply, and can be delivered to major cities such as Mumbai, Delhi, Bangalore, Chennai, Hyderabad, Pune, Ahmedabad, Lucknow, Chandigarh, Jaipur, and more.
Global Rare Meds facilitates the procurement of ZEJULA (Niraparib 100 mg) from verified international sources.
- All medicines are dispatched securely from our fulfillment center in Ambernath, Thane District
- Orders are verified and handled by licensed pharmacists
- Delivery available across India and globally, after fulfilling all legal requirements
We guarantee authentic products, transparent pricing, and timely delivery.
What is the generic name of ZEJULA?
The generic name is Niraparib.
Who manufactures ZEJULA?
ZEJULA is manufactured by Tesaro, Inc.
Is ZEJULA FDA-approved?
Yes, ZEJULA was approved by the FDA in 2017.
What dosage form is ZEJULA available in?
ZEJULA is available as oral capsules, each containing 100 mg of Niraparib.
How is ZEJULA supplied?
Each bottle of ZEJULA contains 90 capsules, each with 100 mg of Niraparib.
What are the storage conditions for ZEJULA?
Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F).
Are generics or biosimilars available for ZEJULA?
No, there are no generic or biosimilar versions of ZEJULA available globally.
How much does ZEJULA cost in India?
To get a quotation, contact:
Phone: +91-99675 15602
WhatsApp: +91-99675 15602
Email: info@globalraremeds.com
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
